2009
Title: Neonatal Alloimmune Thrombocytopenia due to HPA-9b Incompatibility
Authors: Ashok Raj, MD, Vasundhara P. Kailasnath, MD, Salvatore Bertolone, MD and Janice G. McFarland, MD3
Title: Acute Hemolysis After High-Dose Intravenous Immunoglobulin Therapy in Highly HLA Sensitized Patients
Joseph Kahwaji,
* Eva Barker,† Sam Pepkowitz,‡ Ellen Klapper,‡ Rafael Villicana,* Alice Peng,* Robert Chang,* Stanley C. Jordan,* and Ashley A. Vo*
*Comprehensive Transplant Center, †Department of Pharmacy, and ‡Department of Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California
Corresponding author. Correspondence: Dr. Joseph Kahwaji, Comprehensive Transplant Center, Cedars-Sinai Medical Center. 8635 W. 3rd Street, Suite 490, West Los Angeles, CA 90048.
Title: The new platelet alloantigen Cab a: a single point mutation Gln 716 His on the alpha 2 integrin.
Author information: Bertrand G1, Jallu V, Saillant D, Kervran D, Martageix C, Kaplan C.
1Platelet Immunology Unit, INTS, Paris, France.
Title: Evidence for the Specificity for Platelet HPA-1a Alloepitope and the Presenting HLA-DR52a ofDiverse Antigen-Specific Helper T Cell Clones from Alloimmunized Mothers.
Authors: Rachel Rayment, Taco W. Kooij, Wei Zhang, Christian Siebold, Mike F. Murphy, Dave Allen, Nick Willcox and David J. Roberts
Nuffield Department of Clinical Laboratory Sciences and National Blood Service Oxford Centre, UK.
Title: Neonatal Alloimmune Thrombocytopenia is Not What It was. A Lesson Learned from a Large Prospective Screening and Intervention Program
Authors: B. Skogen*,_, A. Husebekk*,_, M. K. Killie* & J. Kjeldsen-Kragh
*Immunology and Transfusion Medicine, University Hospital of North Norway, Tromsø, Norway;
Department of Immunology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway;
Department of Immunology and Transfusion Medicine, Oslo University Hospital, Ulleva°l, Oslo, Norway;
and §Faculty Division Ulleva°l University Hospital, University of Oslo, Oslo, Norway.
Title: Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab’) in an in vivo mouse model of alloimmune thrombocytopenia.
Authors: Bakchoul T, Boylan B, Sachs UJ, Bein G, Ruan C, Santoso S, Newman PJ.
Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, 53201, USA.
Title: Allele frequencies of the human platelet antigen-1 in the Egyptian population
Authors: Abdel Halim Salem12, Kyudong Han3 and Mark A Batzer3*
Department of Anatomy, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain
Department of Anatomy, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA
2008
Title: Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.
Authors: Ghevaert C, Wilcox DA, Fang J, Armour KL, Clark MR, Ouwehand WH, Williamson LM.NHS Blood and Transplant, Department of Haematology, University of Cambridge, Cambridge, United Kingdom. cedric.ghevaert@nhsbt.nhs.uk
Title: Genotyping for human platelet alloantigen polymorphisms: applications in the diagnosis of alloimmune platelet disorders.
Author: Curtis BR.
BloodCenter of Wisconsin, Platelet & Neutrophil Immunology Laboratory, Milwaukee, Wisconsin 53201-2178, USA. brian.curtis@bcw.edu
Title: Fetal and neonatal alloimmune thrombocytopenia
Authors: Eline S.A. van den Akker* MD., Obstetrician, Dick Oepkes MD, PhD.,Obstetrician
Department of Obstetrics, Leiden University Medical Centre, The Netherlands.
Title: T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a-specific, HLA-DRB3*0101-restricted CD4+T cells
Authors: Marie Therese Athlen 1,2, Anne Husebekk 1,2, Mette K Killie 1, Bjorn Skogen 1,2, and Tor B. Stuge 1,2.
Author Affiliations: 1. Department of Immunology and transfusion Medicene, University Hospital of North Norway, Tromso, and 2. Department of Immunology, University of Tromso, Norway.
Title: Ultrastructural localization of glycoprotein IIIa (GPIIIa, beta 3 integrin) on placental syncytiotrophoblast microvilli: implications for platelet alloimmunization during pregnancy.
Authors: Kumpel BM, Sibley K, Jackson DJ, White G, Soothill PW.
Bristol Institute for Transfusion Sciences, National Blood Service, Bristol, UK. belinda.kumpel@nbs.nhs.uk.
https://openaccess.leidenuniv.nl/bitstream/1887/12967/5/02.pdf
Title: Fetal and neonatal alloimmune thrombocytopenia, Best Practice & Research Clinical Obstetrics and Gynaecology 2008.
Authors: Van den Akker ESA, Oepkes D. ( Includes a large bibliography of research papers.)
https://openaccess.leidenuniv.nl/bitstream/1887/12967/9/06.pdf
IVIG for pregnancies at risk for FNAIT: an uncompleted randomised trial comparing 0.5 and 1.0 g/kg bodyweight
2005 – 2008 Leiden University Medical Center, Netherlands. Van den Akker ESA, Westgren M, Husebekk A, Kanhai HHH, Oepkes D, for the NOICH-study group.
Results The Trial Steering Committee recommended the study to be stopped early. After two years of recruitment, only 23 patients of the calculated sample size of two arms of 106 patients had been randomised. For this rare disease, the participation of at least ten other referral centres was needed and anticipated, but could not be realised. Conclusion Whether the effectiveness of a low dose of IVIG is equivalent to the standard dose in the treatment of FNAIT remains uncertain.
Please read report for full details.
Title: Neonatal alloimmune thrombocytopenia associated with Maternal-fetal incompatibility for blood group B.
Authors: Curtis BR, Fick A, Lochowicz AJ, McFarland JG, Ball RH, Petersen J, Aster RH.
Platelet & Neutrophil Immunology Laboratory, BloodCenter of Wisconsin, Milwaukee, WI 53201-2178, USA. brian.curtis@bcw.ed
Title: A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn
Authors: Mette Kjær Killie1, Anne Husebekk 1,2, Jens Kjeldsen-Kragh 3,4, Bjørn Skogen 1,2
1. Department of Immunology and Transfusion Medicine, University Hospital of North Norway, Tromsø
2. Department of Immunology, University of Tromsø
3. Department of Immunology and Transfusion Medicine, Ullevål University Hospital, Oslo and
4. Faculty Division Ullevål University Hospital, University of Oslo, Norway
2007
Dedication in memoriam – Dr. Scott Murphy
HPA-1a/b (PlA1/A2,Zwa/b): the odyssey of an alloantigen system
From the discovery of HPA-1a in 1958 to the present day, studies of this antigen and its allele, HPA-1b, have led to a remarkable number of “firsts” in immunobiology. In this review,we shall trace the history of the HPA-1a/b system and will highlight selected observations made during the past 48 years that have contributed not only to the field of platelet
immunology but also to immunohematology and transfusion medicine in general.
Including: Neonatal alloimmune thrombocytopenia: a 50-year story
C.KAPLAN
I M M U N O H E M A T O L O G Y, V O L U M E 2 3 , N U M B E R 1 , 2 0 0 7
Review: Chronic villitis of unknown etiology
Georges Boog
Department of Obstetrics and Gynecology, Nantes University Hospital, 44035 Nantes Cedex 01, France
Title: Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective
Authors: ESA van den Akker,a D Oepkes,a E Lopriore,b A Brand,c HHH Kanhaia
a Department of Obstetrics, b Division of Neonatology, Department of Paediatrics and c Department of Immunohematology, Leiden University Medical Centre, Leiden, The Netherlands.
Correspondence: Dr ESA van den Akker, Department of Obstetrics, Leiden University Medical Centre, K6-31, PO Box 9600, 2300 RC Leiden, The Netherlands.
Title: Advances in the management of alloimmune thrombocytopenia
Authors: Michael F. Murphy 1, and James B. Bussel 2.
1. National Blood Service, Department of Haematology, John Radcliffe Hospital, University of Oxford, Oxford, UK, and
2. Departments of Pediatrics, Medicine, and Obstetrics and Gynecology, Weill Medical College of Cornell University, New York, NY, USA
2006
Title: Delayed detectability of anti-HPA-3a by the MAIPA assay in a severe neonatal alloimmune thrombocytopenia, but successful transfusion of incompatible donor platelets:
a case report
Authors:K. Schallmoser,1 J. Kutschera,2 S. Macher,1 S. Ulrich,1 P. Eichler,3 S. Panzer 4
& G. Lanzer1
1 Department of Blood Group Serology and Transfusion Medicine and
2 Division of Neonatology, Paediatric Department, Medical University of Graz, Austria
3 Department of Immunology and Transfusion Medicine, Ernst-Moritz-Arndt-University, Greifswald, Germany
4 Clinic for Blood Group Serology, Medical University of Vienna, Austria
Title: Long-Term Effects of Fetal and Neonatal Alloimmune Thrombocytopenia and Its Antenatal Treatment on the Medical and Developmental Outcomes of Affected Children
Author information
Authors: Ward MJ1, Pauliny J, Lipper EG, Bussel JB.
Title: Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia.
Authors: Killie M K, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen J A, Kristiansen I S.
Department of Immunology and Transfusion Medicine, University Hospital of North Norway, Tromsø, Norway
Department of Immunology and Transfusion Medicine, Ullevål University Hospital, Oslo, Norway
Faculty Division Ullevål University Hospital, University of Oslo, Oslo, Norway
Institute of Medical Biology.
Institute of Community Medicine, University of Tromsø, Tromsø, Norway
Deparment of Health Management and Health Economics, University of Oslo, Oslo, Norway
Institute of Public Health, University of Southern Denmark, Odense, Denmark
*MK Killie, Department of Immunology and Transfusion Medicine, University Hospital of North Norway, 9038 Tromsø, Norway. Email mette.kjaer.killie@unn.no
Title: Parallel Randomized Trials of Risk-Based Therapy for Fetal Alloimmune Thrombocytopenia
Authors: Berkowitz, Richard L. MD1; Kolb, E Anders MD2; McFarland, Janice G. MD3; Wissert, Megan RN4; Primani, Andrea4; Lesser, Martin5; Bussel, James B. MD
From the 1Divison of Maternal–Fetal Medicine, Department of Obstetrics and Gynecology, Columbia College of Physicians and Surgeons, New York; 2Division of Pediatric Hematology/Oncology, the Children’s Hospital at Mountefiore, Bronx, New York; 3Blood Center of Southeastern Wisconsin, Milwaukee, Wisconsin; 4Department of Pediatrics, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York; and 5Department of Biostatistics, North Shore Medical Center, Manhasset, New York.
Corresponding author: Richard L. Berkowitz, MD, Division of Maternal–Fetal Medicine Department of Obstetrics and Gynecology, Columbia College of Physicians and Surgeons, 622 West 168th Street, PH 16-66, New York, NY 10032; e-mail: rb2212@columbia.edu
2005
Title: Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion
Authors: Günther Giers1, Folker Wenzel 2, Markus Stockschläder1, Regina Riethmacher1, Horst Lorenz 3, Boris Tutschek 4,5
1. Clinical Hemostaseology and Transfusion Medicine
2. CSL Behring, Germany
3. Biometry and Statistics, Neuberg, Germany
4. Department of Obstetrics, University Hospital Bern, Switzerland and
5. Medical Faculty, Heinrich Heine University Düsseldorf, Germany
Title: HPA polymorphism in sub-Saharan African populations: Beninese, Cameroonians, Congolese, and Pygmies
L. Halle1, A. Bigot2, G. Mulen-Imandy3, K. M’Bayo4, G. Jaeger5, L. Anani6, C. Martageix1, F. Bianchi1, E. Julien1 and C. Kaplan1,*
1. Institut National de la Transfusion Sanguine, Paris, France
2 Faculté des Sciences de la Santé, Unité de recherche en immunologie, Cotonou, Bénin
3. Hôpital général de Douala, Douala, Cameroun
4. Cliniques Universitaires de Kinshasa, Kinshasa, République démocratique du Congo
5. Centres Européens Associés de Biologie Humaine (CEABH), Paris, France
6. Faculté des Sciences de la Santé, Unité de formation et de recherche en Hématologie, Cotonou, Bénin
* *Dr Cécile Kaplan Institut National de la Transfusion Sanguine Laboratoire d’Immunologie Plaquettaire 6 rue Alexandre Cabanel 75739 Paris Cedex 15 France Tel.: +33 01 44 49 30 67 Fax: +33 01 45 67 19 30 e-mail: ckaplan@ints.fr
2004
Title: A new observation – chronic villitis in untreated neonatal alloimmune thrombocytopenia (NAIT): An etiology for severe early intrauterine growth restriction (IUGR) and the effect of intravenous immunoglobulin (IVIG) therapy
Auhors: Janyne Althaus, Edward Weir, Frederic Askin, Thomas Kickler,Karin Blakemore
Title: Follow up of children after antenatal treatment for alloimmune thrombocytopenia
Radder CM, de Haan MJ, Brand A, Stoelhorst GM, Veen S, Kanhai HH.
Department of Obstetrics, Leiden University Medical Center, H4-P, P.O. Box 9600, 2300 RC Leiden, The Netherlands. C.M.Radder@LUMC.nl
PMID: 15363839 DOI: 10.1016/j.earlhumdev.2004.05.007
2003
Title: Nomenclature of human platelet antigens
P. Metcalfe N. A. Watkins W. H. Ouwehand C. Kaplan P. Newman R. Kekomaki
M. De Haas R. Aster Y. Shibata J. Smith V. Kiefel S. Santoso
Title: Fetal microchimerism—what our children leave behind
Author: Michael Verneris – University of Minnesota
2002
Title: Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases.
Authors: A Davoren, P McParland, C A Barnes, W G Murphy Irish Blood Transfusion Service, National Blood Centre, James’s Street, Dublin 8, Ireland.
2001
Title: A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia.
(ClinicalTrials.gov identifier: NCT00194987)
Principal Investigator: James B Bussel, M.D.
The purposes of this study are to provide medical management by giving treatment to the mother that will bring up the fetal platelet count and to minimize the number of invasive procedures to the fetus (which may result in serious fetal injuries).
Estimated Enrollment: 120 Study
Start Date: April 2001
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Actual Primary Completion date: 30 June 2015
History of Changes for Study: NCT00194987.
Latest version (submitted October 9, 2018) on ClinicalTrials.gov
